NanoVibronix Subsidiary ENvue Medical Secures U.S. Patent for Real-Time Imaging Overlay in Navigation Technology
NanoVibronix, Inc. (NASDAQ: NAOV), a medical technology company known for developing non-invasive therapeutic systems, has strengthened its innovation portfolio with the announcement of a newly granted U.S. patent to its subsidiary ENvue Medical Holdings LLC. The United States Patent and Trademark Office (USPTO) officially issued U.S. Patent No. 12,402,953 B2, titled “Insertion Device Positioning Guidance System and Method” on September 2, 2025.
The patent represents a significant milestone for ENvue Medical, formerly known as ENvue Medical Holdings Corp., which became a wholly owned subsidiary of NanoVibronix. It covers a proprietary system that enables clinicians to overlay electromagnetic (EM) navigation data directly onto real-time imaging modalities such as X-ray, computed tomography (CT), ultrasound, and magnetic resonance imaging (MRI).
This innovation addresses one of the long-standing challenges in interventional procedures: the ability to precisely track insertion devices like feeding tubes and catheters in real time without sacrificing accuracy, safety, or workflow efficiency.
The Core of the Innovation
The newly patented technology combines navigation with imaging in a way that few systems on the market currently achieve. Traditionally, navigation systems provide location data of a device relative to a patient’s anatomy, while imaging systems provide real-time visualization of internal structures. However, these two data streams typically remain separate, requiring clinicians to mentally correlate navigation cues with imaging views.
ENvue’s approach merges the two. By directly overlaying EM navigation signals onto live imaging, the system creates a unified visual that shows not only the anatomical structures but also the precise path of the device as it advances.
This real-time overlay can be especially valuable during complex or delicate procedures, such as the placement of feeding tubes in critically ill patients or the navigation of catheters through vascular pathways. Misplacements in such procedures can lead to complications, ranging from prolonged hospitalization to serious adverse events. By reducing uncertainty and increasing accuracy, ENvue’s technology aims to both improve patient safety and streamline procedural workflows.
Clinical Implications
Feeding tube placement is one of the first clinical areas targeted by ENvue’s navigation platform. Feeding tubes are essential for patients who cannot eat or swallow on their own, such as those in intensive care units. Despite being a common procedure, tube placement is not without risk. Incorrect positioning can lead to aspiration, lung injury, or inadequate nutrition delivery.
“Navigation alone is not new,” said Dr. Doron Besser, Chief Executive Officer of NanoVibronix. “What sets ENvue apart is our ability to integrate navigation with imaging in real time, a capability now protected by this patent.”
The overlay system provides clinicians with a visual guide that reduces reliance on guesswork or repeated imaging scans. Instead of inserting a tube blindly and later confirming placement with X-rays—a process that can delay feeding and expose patients to additional radiation—clinicians can see the trajectory in real time as it happens. This not only increases procedural confidence but also minimizes potential complications.
Beyond feeding tube placement, ENvue sees potential for its technology in vascular navigation. Catheter-based interventions in cardiology, neurology, and oncology increasingly demand high precision. By offering a real-time visualization overlay, the system could enhance outcomes in minimally invasive surgeries, interventional radiology, and other fields where precise navigation is critical.
Strengthening Intellectual Property
The newly granted U.S. patent further solidifies ENvue’s growing intellectual property (IP) portfolio, which already includes protections for its core EM navigation platform. Intellectual property is a critical differentiator in the medtech industry, where competition is fierce and technological advancements are quickly emulated.
According to NanoVibronix, this patent not only validates the uniqueness of ENvue’s technology but also establishes barriers for competitors seeking to replicate the integration of navigation and imaging. The company views the patent as a cornerstone for both protecting its existing market position and expanding into new applications.
“With this addition to our global patent portfolio, we believe that ENvue is well-positioned to lead in both current and future clinical applications,” Dr. Besser noted.
Market Impact and Growth Potential
NanoVibronix sees the feeding tube placement market as an immediate growth area for ENvue’s patented system. Feeding tube procedures are performed hundreds of thousands of times annually across hospitals and long-term care facilities. Even incremental improvements in safety and efficiency could translate into meaningful adoption rates and revenue potential.
Moreover, the expansion into vascular navigation opens the door to much larger addressable markets. Vascular interventions, including stent placements, catheter ablations, and embolizations, represent multi-billion-dollar global markets. Technologies that enhance precision and reduce procedural risks are highly valued by clinicians, hospital administrators, and patients alike.
The ability to overlay EM navigation data onto different imaging modalities also increases the system’s versatility. Hospitals often rely on multiple imaging systems depending on the specialty or clinical context. A technology that integrates seamlessly with X-ray, CT, ultrasound, and MRI can fit into a wide range of workflows, boosting its adoption potential.
Competitive Differentiation
The medtech space is full of companies developing navigation and imaging tools, but the integration of the two in real time is rare. Many systems still require clinicians to toggle between navigation screens and imaging displays. ENvue’s overlay technology simplifies this process, allowing doctors to focus fully on the patient and procedure rather than on managing multiple technologies.
This competitive edge could prove especially important in markets where efficiency and outcomes directly influence reimbursement rates. Healthcare systems increasingly prioritize technologies that both improve patient safety and reduce costs by minimizing complications or procedure times.
Strategic Vision for NanoVibronix
For NanoVibronix, the announcement represents more than just a patent win—it underscores the company’s broader strategy to leverage innovation for market leadership. While the parent company is best known for its non-invasive therapeutic devices, including wearable ultrasound systems for pain relief and wound healing, ENvue provides a complementary pathway into interventional navigation and imaging.
By maintaining a diversified portfolio, NanoVibronix strengthens its resilience against market fluctuations and regulatory hurdles. The combination of therapeutic devices and navigation technologies positions the company to address different stages of the patient care continuum, from diagnosis and treatment to ongoing management.
